Patents Assigned to Alpharma AS
-
Publication number: 20080193537Abstract: A dosage form comprising a plurality of pellets, the pellets comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and a controlled-release coating disposed on at least a portion of the core element, the coating comprising an insoluble matrix polymer which is insoluble at pH 1 to 7.5; an enteric polymer which is insoluble at pH 1 to 4 and soluble polymer which is soluble at a pH of 1 to 4, wherein the ratio of the acid soluble polymer to the enteric polymer is 1.45:1 to 2.5:1 on a weight basis, wherein the Cmax of the dosage form differs by less than 20% when administered to a mammalian subject in the fed state compared to the fasted state. Also included are methods of increasing patient compliance by administering the disclosed dosage form to a mammalian subject.Type: ApplicationFiled: May 12, 2006Publication date: August 14, 2008Applicant: ALPHARMA, INC.Inventor: Alfred C. Liang
-
Publication number: 20050143460Abstract: The present invention provides oral pravastatin formulations comprising a physical mixture of pravastatin and at least one pharmaceutically-acceptable excipient, wherein the composition for at least 6 months after its preparation is stable and has a pH of greater than about 7 to less than 9, as well as methods for the preparation and use of these stable formulations.Type: ApplicationFiled: May 7, 2004Publication date: June 30, 2005Applicant: ALPHARMA, INC.Inventor: Alfred Liang
-
Patent number: 6890902Abstract: The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.Type: GrantFiled: February 27, 2001Date of Patent: May 10, 2005Assignee: Alpharma ASInventors: John Sigurd Svendsen, Oystein Rekdal, Baldur Sveinbjornsson, Lars Vorland
-
Publication number: 20050020613Abstract: The invention combines two different subunits with different release profiles in novel sustained-release oral dosage forms. In particular, the oral dosage forms include a subunit that comprises an opioid analgesic and a sustained-release material, wherein the dissolution rate in-vitro of the subunit, when measured by the standard USP Drug Release test of U.S. Pharmacopeia XXVI (2003) <724>, is less than about 10% within about 6 hours and at least about 60% within about 24 hours; less than about 10% within about 8 hours and at least about 60% within about 24 hours; less than about 10% within about 10 hours and at least about 60% within about 24 hours; or less than about 10% within about 12 hours and at least about 60% within about 24 hours; the dosage form providing a duration of therapeutic effect of about 24 hours.Type: ApplicationFiled: September 22, 2003Publication date: January 27, 2005Applicant: ALPHARMA, INC.Inventors: Garth Boehm, Alfred Liang
-
Publication number: 20040241234Abstract: A press-coat formulation comprising a core composition comprising a water-soluble active agent and a waxy material and a coating composition comprising the active agent and a polymer, wherein the coating composition is press-coated onto the core.Type: ApplicationFiled: June 2, 2003Publication date: December 2, 2004Applicant: ALPHARMA, INC.Inventor: Zalman Vilkov
-
Publication number: 20040131552Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.Type: ApplicationFiled: September 22, 2003Publication date: July 8, 2004Applicant: ALPHARMA, INC.Inventor: Garth Boehm
-
Publication number: 20040086566Abstract: In a preferred embodiment of the invention, a solid dosage form is provided comprising a matrix, wherein the matrix comprises (a) a pharmaceutically effective amount of metformin or a pharmaceutically acceptable salt thereof and (b) a waxy matrix material. The invention also provides a method of making a solid dosage form, the method comprising: (a) hot melting a waxy material to form a melt, (b) granulating metformin or a pharmaceutically acceptable salt thereof with the melt to form a granulate; (c) milling the granulate; and (d) compressing granulate to form a matrix.Type: ApplicationFiled: November 4, 2002Publication date: May 6, 2004Applicant: ALPHARMA, INC.Inventor: Xiaoying Zhang
-
Patent number: 6656505Abstract: An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and a wetting agent in liquid suspension. The composition contains floccules of the active ingredient. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.Type: GrantFiled: July 21, 2000Date of Patent: December 2, 2003Assignee: Alpharma USPD Inc.Inventors: Subhas Kundu, Vivek Desai, Andrea Cameron
-
Publication number: 20030175311Abstract: This invention provides DNA sequences coding for Eimeria surface antigens, recombinant vectors containing such DNA sequences, transformed microorganisms containing such vectors and methods for producing the antigens using the transformed microorganisms. Methods are also provided for protecting poultry against coccidiosis using the Eimeria surface antigens. The surface antigens can be administered for such protection either as purified proteins or in the form of DNA encoding the proteins in a suitable viral vector such as vaccinia virus.Type: ApplicationFiled: October 9, 2002Publication date: September 18, 2003Applicant: ALPHARMA INC.Inventors: Mary-Helen Binger, Richard Anthony Chizzonite, Richard Allen Kramer, Peter Thomas Lomedico, Stephen J. McAndrew, Werner Altenburger
-
Publication number: 20030148936Abstract: The present invention provides a cytotoxic 7 to 25-mer peptide with three or more catonic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing the peptides, pharmaceutical compositions containing them, and their use as medicaments, particularly as antibacterial or antitumor agents.Type: ApplicationFiled: February 27, 2001Publication date: August 7, 2003Applicant: ALPHARMA AS.Inventors: John Sigurd Svendsen, Oystein Rekdal, Baldur Sveinbjornsson, Lars Vorland
-
Publication number: 20030022821Abstract: The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.Type: ApplicationFiled: February 27, 2001Publication date: January 30, 2003Applicant: ALPHARMA ASInventors: John Sigurd Svenden, Oystein Rekdal, Baldur Sveinbjornsson, Lars Vorland
-
Publication number: 20020017492Abstract: The present invention relates to a method of separating a first solute A and a second solute B using (simulated) moving bed chromatography. According to the present invention at least one of a) a feed stream; and b) a desorbent stream comprises an organic solvent. The use of different solvent liquids for the feedstream and the desorbent stream results in an increased difference in partition coefficients for solute A and solute B. According to the present invention it is possible to obtain solute A in an extract stream in a form which is more concentrated in comparison to the concentration of solute A in the feedstream.Type: ApplicationFiled: June 1, 2001Publication date: February 14, 2002Applicant: Alpharma AS and Technische Universiteit DelftInventors: Thomas Birger Jensen, Hugo Arthur Honore Billiet, Lucas Antonius Maria Van Der Wielen
-
Patent number: 6077822Abstract: It has been found that sugar acid salts represent beneficial controlled release forms for basic organic drug compounds. Examples of appropriate salts include mono, di, oligo and polysaccharide poly-O-sulphonic acid salts of antibiotics such as tetracyclins and aminoglycosides.Type: GrantFiled: March 13, 1995Date of Patent: June 20, 2000Assignee: Dumex-Alpharma A/SInventors: Hjarne Dyrsting, Torben Koch
-
Patent number: 5958458Abstract: A pharmaceutical multiple unit particulate formulation in the form of coated cores which includes a pharmaceutically acceptable carrier selected from calcium carbonate, calcium silicate, calcium magnesium silicate, calcium phosphate, kaolin, sodium hydrogen carbonate, sodium sulfate, barium carbonate, barium sulfate, magnesium sulfate, magnesium carbonate, and activated carbon, and an active substance in a layer on the outer surface of the cores.Type: GrantFiled: August 1, 1995Date of Patent: September 28, 1999Assignee: Dumex-Alpharma A/SInventors: Tomas Norling, Lone Norgaard Jensen, Jens Hansen
-
Patent number: 5712310Abstract: A stable aqueous suspension including a substantially water-insoluble drug suspended in a completely water-soluble mixture including hydroxypropylmethylcellulose, polyoxyethylene sorbitan monooleate, and xanthan gum.Type: GrantFiled: June 14, 1996Date of Patent: January 27, 1998Assignee: Alpharma USPD, Inc.Inventor: Edward A. Koch
-
Patent number: 5595977Abstract: The present invention relates to novel amino glycoside salts of sucrose-octa-O-sulfonic acid of formula I:([sucrose-octa-O-sulfonic acid.sup.8- ]-[R-(NH.sub.3.sup.+).sub.x ].sub.y -M.sub.z.sup.n+) (I)(x.multidot.y)+(z.multidot.n)=8x.multidot.y.epsilon.N.vertline.[4.ltoreq.x.multidot.y.ltoreq.8], wherein N is the set of natural numbers,x.epsilon.Z.vertline.[4.ltoreq.x.ltoreq.6], wherein Z is the set of integersz.epsilon.N.vertline.[0.ltoreq.z.ltoreq.4],n.epsilon.Z.vertline.[1.ltoreq.n.ltoreq.3],wherein R is a sugar moiety of an amino glycoside and M is a metal ion or an ammonium ion, said compounds being useful for treating ulcerations of the stomach and duodenum.Type: GrantFiled: October 27, 1993Date of Patent: January 21, 1997Assignee: Dumex-Alpharma A/SInventors: Hjarne Dyrsting, Torben Koch
-
Patent number: D476735Type: GrantFiled: November 14, 2001Date of Patent: July 1, 2003Assignee: Alpharma USPD Inc.Inventor: Gerald Zinnbauer